Cybin Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CYBN NYSE American 2834 www.cybin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cybin Inc.

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Jan 15th, 2025 5:07 pm
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Jan 13th, 2025 12:30 pm
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Jan 9th, 2025 10:00 pm
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Dec 10th, 2024 12:30 pm
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Dec 4th, 2024 12:30 pm
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Nov 18th, 2024 12:00 pm
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Nov 14th, 2024 12:30 pm
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - Nov 13th, 2024 12:30 pm
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - Oct 31st, 2024 11:30 am
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Oct 24th, 2024 11:30 am
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 - Oct 3rd, 2024 11:30 am
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program - Oct 1st, 2024 11:30 am
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - Sep 24th, 2024 11:30 am
Cybin Provides Corporate Update on Upcoming Clinical Milestones - Sep 19th, 2024 9:38 pm
Cybin Announces Completion of Previously Announced Share Consolidation - Sep 19th, 2024 11:26 am
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 11:55 am
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation - Aug 27th, 2024 11:01 pm
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder - Aug 13th, 2024 11:30 am
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Aug 8th, 2024 11:36 am
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference - Aug 7th, 2024 11:30 am